Arbutamine vs. Exercise stress testing in patients with coronary artery disease

Evaluation by echocardiography and electrocardiography

Leonard E. Ginzton, Peter E. Pool, Christopher Appleton, Syed M. Mohiuddin, W. Scott Robertson, Geilan D. Ismail, David S. Bach, William F. Armstrong

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Arbutamine is a new beta-adrenergic agonist with potent chronotropic and inotropic properties developed to pharmacologically induce stress, A prospective trial was conducted in five centers with a total enrolment of 45 patients with angiographically documented coronary artery disease. The primary purpose of the trial was to compare the efficacy of arbutamine with symptom-limited exercise in provoking clinical (angina), electrocardiographic (≤0.1 mV ST depression) and echocardiographic (induced wall motion abnormality) evidence of transient stress-induced ischemia. The secondary Purpose was to assess the safety of arbutamine in patients with coronary artery disease. Ischemia was induced at a lower heart rate, systolic blood pressure and pressure-rate product during arbutamine infusion than during exercise. Using angina and/or electrocardiographic evidence of ischemia, arbutamine was more sensitive than exercise in detecting myocardial ischemia (77 vs. 58%, P = 0.021). Using echocardiography, the sensitivity for inducing wall motion abnormalities was 88% with arbutamine and 79% with exercise (P = not significant). Echocardiography in combination with angina and/or electrocardiographic evidence increased the sensitivity to 94% using arbutamine and to 88% with exercise. For the patients with multivessel disease, the sensitivity was 97% and 91%, respectively. No serious adverse events, either cardiac or noncardiac, were associated with arbutamine, and no patient had prolonged ischemia. Although exercise is the preferred method of stress for patients who are able to exercise adequately, arbutamine is at least as sensitive as exercise for the diagnosis of myocardial ischemia, and appears to be a safe and effective alternative to exercise testing in patients unable to exercise adequately.

Original languageEnglish
Pages (from-to)81-89
Number of pages9
JournalInternational Journal of Cardiology
Volume57
Issue number1
DOIs
StatePublished - Nov 15 1996

Fingerprint

Echocardiography
Coronary Artery Disease
Electrocardiography
Exercise
Ischemia
Myocardial Ischemia
arbutamine
Blood Pressure
Adrenergic beta-Agonists
Heart Rate
Safety
Pressure

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Arbutamine vs. Exercise stress testing in patients with coronary artery disease : Evaluation by echocardiography and electrocardiography. / Ginzton, Leonard E.; Pool, Peter E.; Appleton, Christopher; Mohiuddin, Syed M.; Robertson, W. Scott; Ismail, Geilan D.; Bach, David S.; Armstrong, William F.

In: International Journal of Cardiology, Vol. 57, No. 1, 15.11.1996, p. 81-89.

Research output: Contribution to journalArticle

Ginzton, Leonard E. ; Pool, Peter E. ; Appleton, Christopher ; Mohiuddin, Syed M. ; Robertson, W. Scott ; Ismail, Geilan D. ; Bach, David S. ; Armstrong, William F. / Arbutamine vs. Exercise stress testing in patients with coronary artery disease : Evaluation by echocardiography and electrocardiography. In: International Journal of Cardiology. 1996 ; Vol. 57, No. 1. pp. 81-89.
@article{4df60af510184689b6a1007810a6fff0,
title = "Arbutamine vs. Exercise stress testing in patients with coronary artery disease: Evaluation by echocardiography and electrocardiography",
abstract = "Arbutamine is a new beta-adrenergic agonist with potent chronotropic and inotropic properties developed to pharmacologically induce stress, A prospective trial was conducted in five centers with a total enrolment of 45 patients with angiographically documented coronary artery disease. The primary purpose of the trial was to compare the efficacy of arbutamine with symptom-limited exercise in provoking clinical (angina), electrocardiographic (≤0.1 mV ST depression) and echocardiographic (induced wall motion abnormality) evidence of transient stress-induced ischemia. The secondary Purpose was to assess the safety of arbutamine in patients with coronary artery disease. Ischemia was induced at a lower heart rate, systolic blood pressure and pressure-rate product during arbutamine infusion than during exercise. Using angina and/or electrocardiographic evidence of ischemia, arbutamine was more sensitive than exercise in detecting myocardial ischemia (77 vs. 58{\%}, P = 0.021). Using echocardiography, the sensitivity for inducing wall motion abnormalities was 88{\%} with arbutamine and 79{\%} with exercise (P = not significant). Echocardiography in combination with angina and/or electrocardiographic evidence increased the sensitivity to 94{\%} using arbutamine and to 88{\%} with exercise. For the patients with multivessel disease, the sensitivity was 97{\%} and 91{\%}, respectively. No serious adverse events, either cardiac or noncardiac, were associated with arbutamine, and no patient had prolonged ischemia. Although exercise is the preferred method of stress for patients who are able to exercise adequately, arbutamine is at least as sensitive as exercise for the diagnosis of myocardial ischemia, and appears to be a safe and effective alternative to exercise testing in patients unable to exercise adequately.",
author = "Ginzton, {Leonard E.} and Pool, {Peter E.} and Christopher Appleton and Mohiuddin, {Syed M.} and Robertson, {W. Scott} and Ismail, {Geilan D.} and Bach, {David S.} and Armstrong, {William F.}",
year = "1996",
month = "11",
day = "15",
doi = "10.1016/S0167-5273(96)02765-9",
language = "English",
volume = "57",
pages = "81--89",
journal = "International Journal of Cardiology",
issn = "0167-5273",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Arbutamine vs. Exercise stress testing in patients with coronary artery disease

T2 - Evaluation by echocardiography and electrocardiography

AU - Ginzton, Leonard E.

AU - Pool, Peter E.

AU - Appleton, Christopher

AU - Mohiuddin, Syed M.

AU - Robertson, W. Scott

AU - Ismail, Geilan D.

AU - Bach, David S.

AU - Armstrong, William F.

PY - 1996/11/15

Y1 - 1996/11/15

N2 - Arbutamine is a new beta-adrenergic agonist with potent chronotropic and inotropic properties developed to pharmacologically induce stress, A prospective trial was conducted in five centers with a total enrolment of 45 patients with angiographically documented coronary artery disease. The primary purpose of the trial was to compare the efficacy of arbutamine with symptom-limited exercise in provoking clinical (angina), electrocardiographic (≤0.1 mV ST depression) and echocardiographic (induced wall motion abnormality) evidence of transient stress-induced ischemia. The secondary Purpose was to assess the safety of arbutamine in patients with coronary artery disease. Ischemia was induced at a lower heart rate, systolic blood pressure and pressure-rate product during arbutamine infusion than during exercise. Using angina and/or electrocardiographic evidence of ischemia, arbutamine was more sensitive than exercise in detecting myocardial ischemia (77 vs. 58%, P = 0.021). Using echocardiography, the sensitivity for inducing wall motion abnormalities was 88% with arbutamine and 79% with exercise (P = not significant). Echocardiography in combination with angina and/or electrocardiographic evidence increased the sensitivity to 94% using arbutamine and to 88% with exercise. For the patients with multivessel disease, the sensitivity was 97% and 91%, respectively. No serious adverse events, either cardiac or noncardiac, were associated with arbutamine, and no patient had prolonged ischemia. Although exercise is the preferred method of stress for patients who are able to exercise adequately, arbutamine is at least as sensitive as exercise for the diagnosis of myocardial ischemia, and appears to be a safe and effective alternative to exercise testing in patients unable to exercise adequately.

AB - Arbutamine is a new beta-adrenergic agonist with potent chronotropic and inotropic properties developed to pharmacologically induce stress, A prospective trial was conducted in five centers with a total enrolment of 45 patients with angiographically documented coronary artery disease. The primary purpose of the trial was to compare the efficacy of arbutamine with symptom-limited exercise in provoking clinical (angina), electrocardiographic (≤0.1 mV ST depression) and echocardiographic (induced wall motion abnormality) evidence of transient stress-induced ischemia. The secondary Purpose was to assess the safety of arbutamine in patients with coronary artery disease. Ischemia was induced at a lower heart rate, systolic blood pressure and pressure-rate product during arbutamine infusion than during exercise. Using angina and/or electrocardiographic evidence of ischemia, arbutamine was more sensitive than exercise in detecting myocardial ischemia (77 vs. 58%, P = 0.021). Using echocardiography, the sensitivity for inducing wall motion abnormalities was 88% with arbutamine and 79% with exercise (P = not significant). Echocardiography in combination with angina and/or electrocardiographic evidence increased the sensitivity to 94% using arbutamine and to 88% with exercise. For the patients with multivessel disease, the sensitivity was 97% and 91%, respectively. No serious adverse events, either cardiac or noncardiac, were associated with arbutamine, and no patient had prolonged ischemia. Although exercise is the preferred method of stress for patients who are able to exercise adequately, arbutamine is at least as sensitive as exercise for the diagnosis of myocardial ischemia, and appears to be a safe and effective alternative to exercise testing in patients unable to exercise adequately.

UR - http://www.scopus.com/inward/record.url?scp=0030589181&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030589181&partnerID=8YFLogxK

U2 - 10.1016/S0167-5273(96)02765-9

DO - 10.1016/S0167-5273(96)02765-9

M3 - Article

VL - 57

SP - 81

EP - 89

JO - International Journal of Cardiology

JF - International Journal of Cardiology

SN - 0167-5273

IS - 1

ER -